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Abstract
Background: Traumatic brain injury (TBI) results in long-term neurological deficits, which may be mediated in part
by pro-inflammatory responses in both the injured brain and the circulation. Inflammation may be involved in the
subsequent development of neurodegenerative diseases and post-injury seizures. The p75 neurotrophin receptor
(p75NTR) has multiple biological functions, affecting cell survival, apoptotic cell death, axonal growth, and
degeneration in pathological conditions. We recently found that EVT901, a novel piperazine derivative that
inhibits p75NTR oligomerization, is neuroprotective, reduces microglial activation, and improves outcomes in
two models of TBI in rats. Since TBI elicits both CNS and peripheral inflammation, we used a mouse model of
TBI to examine whether EVT901 would affect peripheral immune responses and trafficking to the injured brain.
Methods: Cortical contusion injury (CCI)-TBI of the sensory/motor cortex was induced in C57Bl/6 wild-type mice and
CCR2+/RFP heterozygote transgenic mice, followed by treatment with EVT901, a selective antagonist of p75NTR, or
vehicle by i.p. injection at 4 h after injury and then daily for 7 days. Brain and blood were collected at 1 and
6 weeks after injury. Flow cytometry and histological analysis were used to determine peripheral immune
responses and trafficking of peripheral immune cells into the lesion site at 1 and 6 weeks after TBI. A battery of
behavioral tests administered over 6 weeks was used to evaluate neurological outcome, and stereological
estimation of brain tissue volume at 6 weeks was used to assess tissue damage. Finally, multivariate principal
components analysis (PCA) was used to evaluate the relationships between inflammatory events, EVT901
treatment, and neurological outcomes.
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Results: EVT901 is neuroprotective in mouse CCI-TBI and dramatically reduced the early trafficking of CCR2+ and
pro-inflammatory monocytes into the lesion site. EVT901 reduced the number of CD45highCD11b+ and CD45highF4/80
+ cells in the injured brain at 6 weeks. TBI produced a significant increase in peripheral pro-inflammatory monocytes
(Ly6Cint-high pro-inflammatory monocytes), and this peripheral effect was also blocked by EVT901 treatment. Further, we
found that blocking p75NTR with EVT901 reduces the expansion of pro-inflammatory monocytes, and their response to
LPS in vitro, supporting the idea that there is a peripheral EVT901 effect that blunts inflammation. Further, 1 week
of EVT901 blocks the expansion of pro-inflammatory monocytes in the circulation after TBI, reduces the number
of multiple subsets of pro-inflammatory monocytes that enter the injury site at 1 and 6 weeks post-injury, and is
neuroprotective, as it was in the rat.
Conclusions: Together, these findings suggest that p75NTR signaling participates in the production of the peripheral
pro-inflammatory response to CNS injury and implicates p75NTR as a part of the pro-inflammatory cascade. Thus,
the neuroprotective effects of p75NTR antagonists might be due to a combination of central and peripheral
effects, and p75NTR may play a role in the production of peripheral inflammation in addition to its many other
biological roles. Thus, p75NTR may be a therapeutic target in human TBI.
Keywords: Traumatic brain injury (TBI), p75 neurotrophin receptor (p75NTR), Inflammatory responses, Pro-inflammatory
monocytes, Neuroprotection, Therapeutic target
Background
Traumatic brain injury (TBI) is a huge public health prob-
lem; 1.7 million people sustain a brain injury annually, and
TBI is a contributing factor to a third of all injury-related
deaths (CDC statistics). Mild to severe TBI patients often
suffer long-term disabilities, including cognitive, sensory
and motor dysfunction, dementia, fatigue, epilepsy, head-
aches, depression, and regression of social behavior [1–6].
Despite the large numbers of TBI patients, there is no
effective pharmacological treatment available. Under-
standing the pathogenesis of TBI is critical; TBI triggers
complex and heterogenous pathologic events initiated
by the mechanical injury and hemorrhage and the sub-
sequent progressive secondary injury processes [3]. In
addition to necrotic and apoptotic cell death cascades
[7, 8], these include robust inflammatory responses in
the injured brain including activation of resident micro-
glia and subsequent infiltration of peripheral leuko-
cytes. Chronic TBI patients often display long-lasting
inflammatory responses continuing for months to years
[9, 10]. Such inflammation may contribute to structural
brain abnormalities, cognitive dysfunction [10], and white
matter degeneration (e.g., corpus callosum shrinkage)
[11]. Thus, neuroinflammation likely plays a critical role
in the pathology of chronic TBI.
TBI also increases pro-inflammatory responses in the
peripheral circulation. A recent clinical study shows that
trauma increased the level of MCP-1 (monocyte chemo-
tactic protein-1; also known as CCL2) in the peripheral
blood suggesting that peripheral immune system activa-
tion may provide a surrogate biological index for TBI
impairment [12]. Traumatic spinal cord injury (SCI) in-
creases the number of myeloid cells in the circulation, a
pressage to the infiltration of myeloid cells into the in-
jured spinal cord [13]. Ischemic brain injury releases
soluble damage-associated molecular pattern (DAMP)
molecules that induce peripheral inflammation via toll-
like receptors (TLRs) on peripheral leukocytes [13, 14].
These data suggest that monitoring peripheral myeloid
cells may predict not only the pro-inflammatory re-
sponses of peripheral blood cells but also the trafficking
of myeloid cells into the CNS. Indeed, some studies report
that peripheral blood cells increase pro-inflammatory
genes in response to brain injury [15–17]. Furthermore,
peripheral blood mononuclear cells (PBMCs) isolated
from post-traumatic stress disorder (PTSD) patients have
elevated spontaneous pro-inflammatory cytokine expres-
sion, e.g., interleukin-1 beta (IL-1β), interleukin-6 (IL-6),
and tumor necrosis factor-alpha (TNF-α), providing evi-
dence that PBMCs can be a circulating biological indicator
or biomarker of neuroinflammation after injury [18].
Interestingly, several preclinical studies of SCI and TBI
show that attenuating leukocyte infiltration into the in-
jured CNS in the acute period after trauma often results
in not only inhibition of inflammatory responses in the in-
jured tissue but also better neurological outcomes in the
long term [13, 19–24]. Thus, peripheral inflammation ini-
tiated in response to CNS trauma can feed forward and
exacerbate dysfunction. Further, chronic peripheral in-
flammation can lead to immune suppression, which is a
common feature of brain and spinal cord injuries, adding
significantly to post-injury morbidities [25].
We and others have previously targeted secondary in-
jury processes associated with activation of the p75
neurotrophin receptor (p75NTR) as a neuroprotective
strategy after brain and spinal cord injury [26–29].
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p75NTR, a low-affinity neurotrophin receptor, is a
transmembrane protein in the TNF receptor superfam-
ily (TNFRS-16) [30, 31]. p75NTR binds to all mature
neurotrophins (NTs) with a low affinity; however, the
dimerization with its multiple co-receptors conveys
high-affinity for different ligands and provides ligand
selectivity [32]. For example, p75NTR-Trks (A, B, and
C) dimers have much greater affinity for mature NTs,
mediating cell survival and neurite outgrowth [32–34].
However, when p75NTR forms complexes with sortilin,
it has a high affinity for the pro-neurotrophins (pro-
nerve growth factor (NGF) and pro-brain-derived
neurotrophic factor (BDNF)) and mediates apoptotic
cell death [32, 35], while p75NTR-Nogo/Lingo 1 com-
plexes prefer to bind with myelin-derived ligands
(oligodendrocyte myelin glycoprotein (OMgp) and
myelin-associated glycoprotein (MAG)), resulting in
the inhibition of axonal regeneration [36, 37].
p75NTR is widely expressed in the developing brain,
but its expression is restricted to few regions in the adult
brain [38–40]. However, it is up-regulated, along with its
ligand pro-NGF [26, 41] in various CNS pathologies and
after injury [32]. p75NTR null mice show reduced cor-
tical neuronal cell death after close axotomy [27], re-
duced tissue damage and motor deficits after TBI [42],
and reduced oligodendrocyte apoptosis after SCI [26],
and treatment with a p75NTR antagonist results in
oligodendrocyte protection and improvement in func-
tional recovery after SCI [29]. A recent study has also
shown protection and improved recovery in p75NTR−/−
mice [42]. We have recently studied the effects of a
novel p75NTR antagonist, EVT901, on two models of
TBI in rats [43]. EVT901 is a novel piperazine-derived
compound, which interacts with the first cysteine-rich
domain of the extracellular region, interfering with
p75NTR oligomerization. In vitro binding studies showed
that EVT901 targets p75NTR, but not other members of
the TNFR superfamily tested (TNFR1, TNFR2, HVEM, 4-
1BB, LTR, DR5, BCMA, Fas) [43]. Further, treatment of
both controlled cortical impact (CCI) and lateral fluid per-
cussion (LFP) TBI in rats resulted in a dramatic preserva-
tion of brain tissue volume, inhibition of cell death in both
oligodendrocytes and cortical neurons, and promotion of
neurological recovery [43]. Although p75NTR has rarely
been observed on microglia, treatment with EVT901 dra-
matically reduced microglial activation in the lesion area,
suggesting that p75NTR blockade could reduce central
neuroinflammation. There is evidence for expression of
p75NTR in leukocytes [44–46] and mesenchymal stem
cells [47, 48], and in light of the evidence linking CNS and
peripheral inflammation, we wondered whether the dra-
matic effects of EVT901 might reflect an additional action
on peripheral immune responses to TBI. We chose a CCI-
TBI since cortical contusions are common in human TBI,
and this type of injury is characterized by a “blooming” of
blood-brain barrier breakdown and hemorrhage, with
many peripheral cells entering the brain over the first few
days after injury [19, 49]. We found that mouse mono-
cytes express p75NTR and that TBI increases their num-
ber at a week following injury, while sham injuries do not.
One week of treatment with EVT901 blocks this effect of
TBI, suggesting a CNS injury-specific effect. We found
that blocking p75NTR with EVT901 reduces the expan-
sion of pro-inflammatory monocytes, and their response
to lipopolysaccharide (LPS) in vitro, supporting the idea
that there is a peripheral EVT901 effect that blunts in-
flammation. Further, one week of EVT901 blocks the ex-
pansion of pro-inflammatory monocytes in the circulation
after TBI, reduces the number of multiple subsets of pro-
inflammatory monocytes that enter the injury site at 1 and
6 weeks post-injury, and is neuroprotective, as it was in
the rat. Together, these results support the idea that there
is a central-to-peripheral-to-central loop of inflammatory
responses that contribute to CNS dysfunction after injury
and identify p75NTR as a target in both central and per-
ipheral inflammation. Thus, p75NTR may be a unique
therapeutic target for immune modulation in human TBI.
Methods
Controlled cortical impact TBI
Adult C57BL/6 wild-type (WT) mice (3–5 months old,
Jackson Laboratory) and CCR2+/RFP transgenic heterozy-
gous mice (backcrossed with C57Bl/6 mice; [50]) were
used for this study. Mice were housed individually and
maintained on a 12-h light/dark cycle with food and
water. All animal experiments were approved by the In-
stitutional Laboratory Animal Care and Use Committee
of University of California San Francisco and performed
in compliance with NIH guidelines. Surgical procedures
were carried out aseptically under isoflurane anesthesia.
The toe pinch-reflex test was used to determine the ef-
fectiveness of the anesthetic prior to surgery. Lacrilube
ophthalmic ointment (Allergan Pharmaceuticals, Irvine,
CA) was applied to the eyes prior to surgery. Body
temperature was monitored using a rectal thermal probe
and maintained at 37.5 ± 0.5 °C using a heating pad.
To generate the TBI, a controlled cortical impact (CCI)
device (Custom Design & Fabrication, Inc., Sandston, VA)
was used as described previously [43, 51]. Briefly, mice were
mounted in a Kopf stereotaxic frame under isoflurane
anesthesia (5 % induction, 1.5–2 % maintenance). A unilat-
eral craniectomy (4.0-mm diameter) was produced in the
skull between bregma (+2 to −2 mm) and between 1.0 and
3.0 mm laterally from bregma using a drill. Moderate con-
tusion brain injury was generated using the CCI device ori-
ented at a 60° angle to the cortical surface and with a 3-
mm-diameter impactor tip, over the left somato-motor cor-
tex. A 2.0-mm displacement at 4 m/s velocity with a dwell
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time of 150 ms was used. The injury sites were closed, and
the animals maintained at 37.5 °C in a Thermocare®, Inten-
sive Care Unit with Dome Cover (Thermocare, Inclined
Village, NV). Sham-injury controls had all procedures,
including the craniectomy. Animals were administered
50 mg/kg of cefazolin (Ancef, Novation, LCC, Irving,
TX) perioperatively and 1 day post-operatively and
1.2 mg/kg of buprenorphine HCl CIII SR (Zoopharm,
Windsor, CO, USA) once perioperatively.
Drug treatment
One milligram per kilogram of EVT901 (Evotec, France)
or vehicle (PBS) was injected i.p. once per day for 7 days
starting at 4 h post-injury. This dose was chosen based
on our previous study [43].
Measurement of RFP+ monocyte signals from CCR2+/RFP
Tg mice
CCR2+/RFP Tg mice were euthanized at 7 days after
TBI and transcardially perfused with PBS, followed by
4 % paraformaldehyde. Brains were removed, post-
fixed, and cryoprotected in 30 % sucrose. Thirty-
micrometer sections were cut on a cryostat (Microm
HM550, Thermo Fisher Scientific, Cambridge, MA,
USA). To quantitate the infiltrating RFP+ monocytes, a
total of five brain sections from every 10th section from
the region of interest (ROI; bregma 1.5 to −1.5 mm)
were used. After washing with PBS, brain tissue sec-
tions were mounted with mounting media (Prolong
Gold with DAPI, Invitrogen, Grand Island, NY, USA).
Brain tissue sections were photographed with ×20 ob-
jective on a BIOREVO all-in-one fluorescence micro-
scope with a BZ-9000 Generation II analyzer (Keyence
microscopes, Itasca, IL, USA), and the stitched image
from a whole brain section was obtained using the
Image Stitching Function, which links XY coordinate
positions and is able to create a wide-view image. To
measure the infiltrating RFP+ monocytes in the injured
brain in CCR2+/RFP Tg mice, we used proportional area
(P.A.) measurements based on previous studies with
minor modifications [21, 52]. Briefly, a stitched image was
opened using the BZ-9000 Generation II analyzer (BZ-
9000 Generation II, Keyence microscope). The “hybrid cell
count” function for fluorescence image types was used. To
determine the specific target area, the ipsilateral or contra-
lateral hemisphere was contoured using the “target area”
function. After setting the threshold on the RFP-positive
signal on the image, the RFP-positive area and the thre-
sholded area were derived. The total areas from the ipsi-
lateral and contralateral hemispheres were measured by
the “area measurement” function. P.A. was then calculated
as a ratio: (the area of the RFP signal/total area of the ipsi-
lateral or contralateral tissue)*100. A total of 16 CCR+/RFP
Tg mice were used (n = 5 per TBI groups, vehicle vs
EVT901; and n = 3 per sham groups, vehicle vs EVT901).
Histology and immunocytochemistry for the CCI-TBI
subjects
C57Bl/6 mice were euthanized at 7 days post-injury and
transcardially perfused with PBS, followed by 4 % parafor-
maldehyde. Brains were removed, post-fixed, and cryopro-
tected in 30 % sucrose. Thirty-micrometer sections were
cut on a cryostat (Microm HM550, Thermo Fisher Scien-
tific). Brain sections were treated with blocking buffer
(10 % goat serum/0.1 % BSA/0.01 % Triton X-100) for 1 h
at RT and stained O/N at 4 °C with antibodies against
CD45-FITC (1:200, eBioscience, San Diego, CA, USA),
CCR2 (1:100, Abcam, Cambridge, MA, USA), CD11b
(1:200, Millipore, Darmstadt, Germany), and F4/80
(1:200, AbD Serotec, Raleigh, NC). After washing with
PBS, three times, secondary Abs (1:200; anti-Rabbit-
Cys3; Jackson ImmunoLaboratories, West Grove, PA,
USA, anti-Hamster rat-Cys3; Jackson ImmunoLabora-
tories) were added and incubated for 1 h at RT. Slides
were washed with PBS for 5 min, three times, and then
coverslipped with mounting media with DAPI (Pro-
long Gold with DAPI, Invitrogen). The stained brain
tissue sections were photographed with a ×20 object-
ive using the BIOREVO all-in-one fluorescence micro-
scope (BZ-9000 Generation II, Keyence microscope),
and positive signal was measured using BZ-9000 Gen-
eration II analyzer (Keyence).
Measurement of P.A. for double-positive signals from
immuno-stained tissue sections
To quantify the double-positive cells (CD45+ with
CCR2+, or F4/80+) in the injured brain tissues, we ap-
plied P.A. measurements using the “single extraction”
function using the BZ-9000 Generation II analyzer (BZ-
9000 Generation II, Keyence microscope). Briefly, a
total of five brain tissue sections from every 10th sec-
tion from the regions of interest (ROI; from bregma
+1.5 to −1.5 mm) were selected for measuring the P.A.
of immuno-stained brain sections from the ROI. Using
the hybrid cell count function, for fluorescence images,
the target area was specified, and the ipsilateral or contra-
lateral hemisphere was contoured and the threshold set
for CD45-positive signal, CCR2-positive signal, or F4/80-
positive signal on the image. The total area of the ipsilat-
eral and contralateral hemisphere was then measured.
The P.A. was calculated for each hemisphere as a ratio:
(the area of double-positive signal/total area of the ipsilat-
eral tissue)*100. A total 16 C57Bl/6 WT mice were used:
n = 5 per TBI group (vehicle vs EVT901) and n = 3 for
sham groups (vehicle vs EVT901).
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Determination of brain tissue damage
To determine if EVT901 protects the brain from damage
after TBI, we measured the areas of the injured brain at
7 days after TBI with or without EVT901. A total of five
sections from every 10th brain sections through the ROI
(bregma 1.5 to −1.5 mm) were selected. The 30-μm-
thick brain tissue sections were stained with cresyl violet
and mounted with DPX mounting media (Sigma). The
total area of the ipsilateral and contralateral hemispheres
was measured using the “area measurement” function
using BZ-9000 Generation II analyzer (BZ-9000 Gener-
ation II, Keyence microscope). Brain damage was deter-
mined as (area of the ipsilateral hemisphere/area of the
contralateral hemisphere)*100. A total of 32 mice (16
CCR+/RFP Tg mice and 16 C57Bl/6 WT mice) were used:
n = 5 per TBI group (vehicle vs EVT901) and n = 3 for
sham groups (vehicle vs EVT901).
Flow cytometric analysis
Determination of RFP-positive cells in the circulation
To examine if TBI affected RFP-positive monocytes in
the circulation, we used flow cytometry with leukocytes
isolated from CCR+/RFP Tg mice. Blood was obtained by
cardiac puncture from CCR+/RFP Tg mice at 7 days after
TBI with or without EVT901 treatment. Leukocytes
were isolated as described previously [13]. Briefly, 200 μl
of blood was treated with 2 ml of ×1 RBC lysis buffer
(eBioscience) for 5 min at RT and 20 ml of Dulbecco’s
phosphate-buffered saline (DPBS) (cell culture facility at
UCSF) were added. Leukocytes were obtained by centri-
fuging at 350×g for 5 min. The cell pellet was re-
suspended with Fluorescence-activated cell sorter
(FACS) buffer (0.02 % NaN3/1 % FBS/DPBS, pH 7.4).
The isolated leukocytes were run with flow cytometry
(LSRII, BD Bioscience, San Jose, CA, USA), and RFP+
cells were determined. For negative control, leukocytes
were isolated from WT mice and run with flow cytome-
try. To determine cell viability, aqua amine reactive dye
(AARD) (LIVE/DEAD® Fixable-Aqua Dead Cell Stain
Kit, Invitrogen) was used. A total of 16 CCR+/RFP Tg mice
were used: n = 5 per TBI group (vehicle vs EVT901) and
n = 2–3 for sham group (vehicle vs EVT901).
Determination of p75NTR expression in the circulation
after TBI
To examine if TBI up-regulates p75NTR expression in
the circulation, we used flow cytometry with leukocytes
isolated from C57Bl/6 mice at 1 and 6 weeks after TBI
with or without EVT901. The leukocytes were isolated
as described earlier. The isolated cells were incubated
with AARD according to the manufacturer’s protocol.
For intracellular staining, the isolated leukocytes were
fixed with IC fixation buffer (eBioscience) and treated
with permeabilization buffer (eBioscience). The fixed
leukocytes were stained with rabbit anti-p75NTR
(Abcam) for 30 min at 4 °C and then stained with anti-
rabbit-PE Ab (Invitrogen) for 30 min at 4 °C. The
p75NTR-expressing cells were identified by flow cy-
tometry (LSRII, BD Bioscience). Non-specific signal
was determined using isotype control Ab. A total of 34
C57Bl/6 WT mice were used: n = 4–5 per TBI group
(vehicle vs EVT901) and n = 3–5 for sham groups (ve-
hicle vs EVT901).
Determination of Ly6Chigh monocytes in the circulation
To examine if TBI affects Ly6Chigh inflammatory
monocytes in the circulation, we used flow cytometry
with leukocytes isolated from C57Bl/6 mice at 1 and
6 weeks after TBI with or without EVT901 treatment.
The isolated cells were incubated with AARD according
to the manufacturer’s protocol. The leukocytes were
stained with anti-mouse CD16/32 Fc blocking Ab (1:10,
eBioscience) at 4 °C for 10 min. After adding anti-
Ly6C-PE/Cy7 Ab (BioLegend) and anti-CD11b-PE/Cy5
Ab (eBioscience), the leukocytes were incubated at 4 °C
for 30 min. After washing with PBS, the cells were re-
suspended in fixative (1 % platelet function assay
(PFA)). The stained leukocytes were identified by flow
cytometry (LSRII, BD Bioscience). Non-specific signal
was determined using isotype control Ab. A total of 33
C57Bl/6 WT mice were used: n = 4–7 per TBI group
(vehicle vs EVT901) and n = 3 for sham groups (vehicle
vs EVT901).
Determination of the recruitment of monocytes into the
injured brain
To determine if TBI induces recruitment of Ly6Chigh in-
flammatory monocytes into the injured brain, we used
flow cytometric analysis. Brain cells were obtained as de-
scribed previously [53, 54]. Briefly, mice were perfused
with PBS, and brains were obtained from C57Bl/6 WT
mice at 1 and 6 weeks after TBI with or without
EVT901 treatment. The ipsilateral hemisphere was dis-
sected in the HBSS media and mechanically dissociated
with the syringe followed by pipetting with 1-ml tips. To
the cell suspensions, DNase I (0.025 U/ml of final concen-
tration) and collagenases (0.05 % of final concentration)
were added and incubated for 15 min at 37 °C. The cell
suspensions were centrifuged, and the cell pellets were re-
suspended with 1 % FBS/HBSS. The cell suspensions were
strained in a 40-μm nylon cell strainer (Becton Dickinson)
and centrifuged at 1500 rpm for 5 min. The cells were
re-suspended with 30 % Isotonic Percoll solution (GE
Healthcare Bio-Science AB, Uppsala, Sweden) and over-
lay in the 70 % Percoll solution followed by centrifuging
at 500×g for 25 min at RT without braking. The cells in
the interphase were obtained and re-suspended with
FACS buffer (0.02 % NaN3/5 % FBS in DPBS). The
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isolated cells were incubated with AARD according to
the manufacturer’s protocol. The cells were pre-stained
with anti-mouse CD16/32 Fc blocking Ab (1:10,
eBioscience) at 4 °C for 10 min followed by adding Abs:
anti-CD45-BV605 (BioLegend, San Diego, CA, USA),
anti-Ly6C-PE/Cy7 (BioLegend), anti-CD11b-PE/Cy5
(eBioscience), and F4/80-BV421 (Biolegend). After in-
cubating at 4 °C for 30 min, the cells were washed and
re-suspended with a fixative (1 % PFA). The stained
leukocytes were identified by flow cytometry (LSRII,
BD Bioscience). To remove false-positive signals from
multiple fluorochromes, each fluorescence compensa-
tion control was run by flow cytometry (LSRII, BD
Bioscience). Non-specific signal was determined using
isotype control Ab. A total of 36 C57Bl/6 WT mice
were used: n = 5–7 per TBI group (vehicle vs EVT901)
and n = 3–4 for sham groups (vehicle vs EVT901).
Data analysis
Flowjo software (Tree Star, Ashland, OR) was used for
analyzing data from flow cytometry. Firstly, a fluores-
cence compensation was processed with Flowjo software
with each fluorochrome control. For blood cells, at least
100,000 events were counted. Leukocytes were initially
gated by their characteristic forward and side scatter pro-
files, which represent size and granularity, respectively. Vi-
able cells were determined by AARD non-labeled cells.
For brain cells, 500,000 events were counted. The brain
cells were initially gated by live cells. Gated cells were then
analyzed for fluorescent intensity.
To determine absolute number of total cells, the cell
concentration was calculated with counting beads
(CountBright™ Absolute Counting Beads for flow cytom-
etry, Molecular Probes) according to the manufacturer’s
protocol.
EVT901 effects on p75NTR expression by LPS in vitro
To determine if p75NTR is involved in the pro-
inflammatory responses of leukocytes, we used an in vitro
culture system. Blood was obtained from C57Bl/6 mice.
Leukocytes were isolated as described previously [13].
Briefly, blood was obtained by cardiac puncture and was
treated with ×1 RBC lysis buffer (eBioscience) for 5 min at
RT and added DPBS (cell culture facility in UCSF). Leuko-
cytes were obtained by centrifuging at 350×g for 5 min.
The cell pellet was re-suspended with RPMI media with
1 % FBS. 1 × 106 cells were treated with LPS (10 ng/ml)
and EVT901 (30 nM), EVT901 (30 nM) alone, or vehicle
alone. After 24-h incubation at 37 °C, cells were isolated
by centrifugation and used for flow cytometric analysis.
The supernatant was used for TNFα ELISA.
The isolated cells were stained with CD11b-PE/Cy5
(eBioscience), a pan monocyte/macrophage marker, for
30 min at 4 °C. After washing with PBS, the leukocytes
were fixed with IC fixation buffer (eBioscience). And
then, the cells were placed in permeabilization buffer
(eBioscience). The fixed leukocytes were stained with
rabbit anti-p75NTR (Abcam) for 30 min at 4 °C and
then stained with anti-rabbit-PE Ab (Invitrogen) for
30 min at 4 °C. The p75NTR expressing CD11b+ cells
were identified by flow cytometry (LSRII, BD Bioscience).
The cell supernatant was used for determining TNFα pro-
duction using mTNFα ELISA kit (Invitrogen) according to
a manufacturer’s manual. Briefly, 50 μl of standard diluent
buffer was added in the TNFα pre-coated eight-well strips
followed by adding 50 μl of cell supernatant. And then,
50 μl of biotinylated mouse TNFα Biotin Conjugate solution
was added and incubated for 90 min at RT. After washing
with buffer, 100 μl of streptavidin-HRP working solution
was added in the wells and incubated for 30 min at RT.
After washing, the wells were incubated with 100 μl of Sta-
bilized Chromogen for 30 min at RT, and then, the reaction
stopped by adding 100 μl Stop solution. The wells were read
on a 450-nm plate reader using Magellan software (GENios
plate reader, TECAN, Switzerland). A total of six mice were
used for the in vitro experiments. Data were obtained from
three independent in vitro experiments.
Volumetric analysis: the Cavalieri probe method
To determine if EVT901 affected tissue damage after
TBI, the estimated volume of the injured brain was mea-
sured by systematic volumetric analysis. Briefly, at
6 weeks after TBI, the brains of PFA-perfused animals
were collected and cut at 30 μm as described above. For
each mouse, eight brain tissue sections (every 10th sec-
tion between +1.5 and −1.5 mm from Bregma) were
chosen for stereological analysis and stained with cresyl
violet. The Cavalieri principle was used to generate un-
biased estimates of volume using Stereo Investigator
software (MBF Bioscience, Williston, VT). As a Cavalieri
probe, a 150-μm square grid was placed over the brain
tissue section and all the grid points that overlay the
areas of interest were marked. The area of the cerebral
cortex was indicated as in Fig. 8b (red for ipsilateral to
the TBI, blue for contralateral). All eight brain tissue
sections were evaluated by marking the grid points,
which generated unbiased estimations of area. The vol-
ume was estimated by summing the areas and multiply-
ing by the tissue thickness using Stereo investigator
software (MBF Bioscience). Gunderson Coefficient of
Error, m = 1, was evaluated to determine the accuracy of
the stereological estimation and was under 0.05 (not
shown) in this study (n = 4–5 per group).
Behavioral outcome measures
A battery of behavioral tests was performed to assess
motor function after TBI. A total of N = 10–12 per
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group were used for the behavioral testing (groups: TBI
with and without EVT901 and sham with and without
EVT901).
Paw placement test
Paw placement assessments were performed as previ-
ously described [43, 51]. Briefly, mice were placed in a
clear plastic cylinder with two mirrors placed at angles
such that both sides of the mice were clearly visible.
Mouse behaviors were recorded with a digital camera
for 3 min, and the number of times the mice placed its
left, right, or both forepaws against the cylinder during
weight supported movements was recorded. Individual
placements were scored as either “left” or “right” when
0.5 s or more passed without the other limb contacting
the cylinder. If both forepaws were used for weight-
supported movements within 0.5 s of each other, a score
of “both” was given. Scoring was performed using video
playback by trained raters who were blind to experimen-
tal condition. Mice were tested before surgery, at 1 day
after TBI and then weekly thereafter for 6 weeks.
IBB forelimb rating scale (cereal test)
Fine forelimb motor function was assessed using the Ir-
vine, Beatties, and Bresnahan (IBB) cereal eating test as
described previously with minor modification [51, 55, 56].
Briefly, mice were individually placed in their home cage.
Consistently, sized spherical- and doughnut-shaped pieces
of cereal were given to mice. Eating behavior was recorded
while consuming both cereal shapes. Paw use was evalu-
ated following the standardized scoring system for com-
mon forelimb behaviors including joint position, object
support, digit movement, and grasping technique. An IBB
score was assigned using the 10 point (0–9) scale as previ-
ously described [56].
Beam-walking test
Mice were evaluated for motor deficits after TBI using
the beam-walking test, which can discriminate fine
motor coordination differences between injured and
sham-operated mice [57, 58]. The beam-walking device
consists of a narrow plastic beam (5 mm wide and
120 cm in length) suspended 1 m above the ground over
a foam pad. The mouse was placed on the end of the
beam, and the number of footfaults for the forelimb
contralateral to the brain injury was assessed while walk-
ing the length of the beam. A basal level of performance
was achieved following 3 days of pre-training prior to
surgery, with an acceptance level of fewer than three
footfaults per trial. The test was performed at 1 day after
TBI and then weekly for 6 weeks.
Inclined beam-walking test
An inclined beam-walking test as described in Chang et
al. [59] was also used. Mice were placed at the high end
of a 120-cm-long plastic beam (5 mm wide) set at 10°
above horizontal, and the number of footfaults for the
forelimb contralateral to the TBI was assessed while
walking the length of the beam.
Rearing test
A rearing test was used to assess general motor function
[60, 61]. The number of rearing episodes that mice made
while exploring a clear plastic cylinder for a 3-min period
was recorded.
Grid-walking test
To assess motor control deficits, we also used a grid-
walking task. A wire mesh grid with 1-in. spaces was
used to measure the number of incorrect foot place-
ments, i.e., the number of times the foot slipped
through the grid [13]. The ability to traverse the wire
grid was evaluated at 35, 36, and 37 days after injury.
There were three trials daily with a total of nine trials
for the test.
Adhesive removal test
To assess sensorimotor deficits, we used the adhesive re-
moval test [62]. Briefly, a small rectangular sticker (3 mm×
4 mm) was placed on the front paw, and the time to re-
move the sticker was measured.
Forelimb contraflexion test
The forelimb contraflexion test was performed as previ-
ously described [57]. Mice were temporarily suspended
by tail above a flat surface, and a score was assigned
based on the following criteria; 5 = normal response
characterized by outstretched forelimb making contact
with the flat surface (normal mice tend to extend their
front limbs spontaneously), 4 =mouse turns preferen-
tially to one side while suspended, 3 = unilateral turning
behavior and contraflexion of contralateral forelimb to
an angle of less than 90° degree from the normal out-
stretched position, 2 = unilateral turning behavior and
contraflexion of contralateral forelimb to an angle of
greater than 90° degrees from the normal outstretched
position, 1 = unilateral turning behavior and contraflex-
ion of contralateral forelimb to an angle of more than
90° degrees from the normal outstretched position with
no effort made to use limb to prevent a perceived fall.
Statistical analysis
Statistical analysis was performed using SPSS v.19 with
base, regression, advanced models plug-ins (IBM), and
missing values plug-ins. Principal component analysis
was performed in SPSS and the R Shiny package for
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principal component analysis (PCA) syndromic plots.
Principal components (PCs) were extracted using
eigenvalue decomposition of the correlation matrix. PC1
was retained using established statistical rules of (1) eigen-
value >1, (2) scree plot, (3) PC overdetermination with
multiple loadings >|0.6|. For PC interpretation, we consid-
ered all loadings >|0.3|. PC scores were calculated using
the regression method, and hypothesized group difference
used GraphPad Prism 5 was used for bar graphs (GraphPad
Software, La Jolla, CA). Data are expressed as means ±
SEM. Two-way ANOVA was used for flow cytometric ana-
lysis followed by Tukey’s post hoc test. One-way ANOVA
was used for in vitro cell culture experiment and
histological analysis followed by Tukey’s post hoc test.
Two-group comparisons were done by unpaired T
tests. Statistical significance was defined at p ≤ 0.05.
Statistical results are presented in the figure legends.
Results
EVT901 treatment reduces the absolute number of
p75NTR-expressing leukocytes in the circulation after TBI
in mouse
Several studies have reported that human leukocytes ex-
press p75NTR [44, 45], raising the possibility that
p75NTR may be involved in immune function and that
EVT901 may have peripheral effects on inflammation
after TBI. Mouse leukocytes express p75NTR (Fig. 1).
Both CD11b+ and Gr1+ populations isolated using flow
cytometry included p75NTR+ cells, and the number of
p75NTR+ cells was increased at 7 days post-TBI (Fig. 1).
Treatment for 7 days with EVT901 blocked this in-
crease. These data support the possibility that p75NTR
could be involved in mediating the early inflammatory
responses in the circulation after TBI.
Blocking p75NTR reduces the pro-inflammatory response
of monocytes to LPS in vitro
In order to test whether p75NTR might mediate pro-
inflammatory responses in the periphery, we asked whether
EVT901 would affect the response of pro-inflammatory
monocytes in vitro to LPS stimulation. Since Ly6Chigh and
Ly6Cint monocytes are characterized as the “pro-inflamma-
tory monocytes” [63–68], we evaluated the population of
CD11b + Ly6Cint-high inflammatory monocytes in the iso-
lated leukocytes. Treatment with 10 ng/ml of LPS increased
the population of CD11b + Ly6Cint-high pro-inflammatory
monocytes in the isolated leukocytes (Fig. 2b–d). In order
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Fig. 1 EVT901 treatment reduced p75NTR-expressing leukocyte in the circulation at 7 days after TBI. a–c Leukocytes were obtained from normal
C57Bl/6 mouse blood, and cell type was identified by flow cytometry. p75NTR is expressed on CD11b+ cells (b) and Gr-1+ cells (c). d, e Blood
was obtained from C57Bl/6 mice at 7 days after TBI with or without EVT901 treatment and isolated leukocytes were immuno-stained with
p75NTR Ab. TBI increased the absolute number of p75NTR+ cells, while EVT901 treatment significantly reduced the number in the circulation.
One-way ANOVA showed a significant effect of condition (F3,9 = 4.62, p = 0.03, η2 = 0.61, power = 0.71; Tukey’s post hoc test: TBI vehicle vs
TBI-EVT903, p = 0.03). n = 2–3 for sham and n = 4 for TBI. Asterisk indicates p < 0.05
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CD11b + Ly6Cint-high inflammatory monocyte, cultures
were treated with EVT901. Thirty nanometer of
EVT901 treatment significantly inhibited the expansion
of CD11b + Ly6Cint-high inflammatory monocytes by
LPS (Fig. 2d).
Elevated TNFα production is a hallmark of pro-
inflammatory stimulation [69–71]. We tested whether
EVT901 treatment inhibits LPS-induced TNFα produc-
tion in the isolated leukocytes. LPS increased TNFα
production, as determined by TNFα ELISA, and
EVT901 treatment significantly reduced TNFα pro-
duction (Fig. 2e). These results suggest that EVT901
has anti-inflammatory effects through blocking the
p75NTR signaling pathway in leukocytes and supports
the hypothesis that p75NTR is involved in the pro-
inflammatory responses of peripheral monocytes. We
next examined the effects of TBI and EVT901 on this
population in the circulation in vivo.
EVT901 treatment inhibits the production of CD11b +
Ly6Cint-high inflammatory monocytes in the circulation
after TBI
Ly6Chigh monocytes have been shown to emerge from
the bone marrow and enter the peripheral blood stream
where they are directed to sites of tissue injury and in-
flammation [72, 73]. CCI-TBI dramatically increased the
number of circulating CD11b + Ly6Cint-high monocytes
at 7 days after injury. Further, this effect was signifi-
cantly reduced by 7-day treatment with EVT901
(Fig. 3). The total absolute number of CD11b +
Ly6Cint-high inflammatory monocytes was reduced at
6 weeks after TBI, regardless of treatment, suggesting














































































Fig. 2 EVT901 treatment inhibited the inflammatory response to LPS in isolated leukocytes in vitro. The isolated leukocytes (1 × 106 cells) were
treated with 10 ng/ml LPS, LPS + EVT901 (30 nM), EVT901, or vehicle. After 24-h incubation at 37 °C, cells were isolated by centrifugation and the
cell type identified by flow cytometry. a CD11b + Ly6C+ monocytes consisted of two distinct subpopulations: Ly6Clow monocytes and Ly6Cint-high
pro-inflammatory monocytes. b–d LPS treatment increased the proportion of the population that was the CD11b + Ly6Cint-high, while EVT901
treatment reduced it. Data were obtained from three independent experiments. One-way ANOVA showed a significant effect of condition
(F4,14 = 7.03, p = 0.007, η
2 = 0.76, power = 0.92; Tukey’s post hoc test, *p < 0.05, **p < 0.005). e TNFα in the supernatant was measured using
ELISA. EVT901 treatment inhibited TNFα production by LPS. Data were obtained from three independent experiments. One-way ANOVA
showed a significant effect of condition (F4,15 = 13.81, p = 0.0004, η2 = 0.85, power = 0.999; Tukey’s post hoc tests,*p < 0.05, ##p < 0.001)
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a normalization of pro-inflammatory cell populations
in the blood.
EVT901 treatment reduces the absolute number of total
Ly6Cint-high monocytes in the injured brain after TBI
In order to examine if the inhibition of peripheral Ly6Cint-
high pro-inflammatory monocytes is reflected in a reduc-
tion of the recruitment of Ly6Cint-high monocytes in the in-
jured brain after TBI, we used flow cytometry to identify
those cells from brain homogenates. CD45 Ab was applied
along with Abs to CD11b and Ly6C Ab. We were able to
distinguish leukocytes of peripheral origin (CD45high) and
residential microglia (CD45low) (Fig. 4a). Here, we analyzed
pro-inflammatory monocytes (CD45highCD11b + Ly6Cint-
high), which are increased in the injured brain after TBI
(Fig. 4a–c). There was a significant reduction of
CD45highCD11b + Ly6Cint-high monocytes in the injured
brain after EVT901 treatment compared to vehicle-treated
mice after TBI (Fig. 4a–c). These data suggested that
p75NTR is involved in not only differentiation of Ly6Cint-
high pro-inflammatory monocytes in the circulation but
also recruitment of these pro-inflammatory monocytes
into the injured brain, perhaps by a variety of potential
mechanisms. Further, the TBI-induced inflammatory cell
increase was maintained at 6 weeks in the brain as op-
posed to the return to baseline seen in the blood (Fig. 4),
and the EVT901 treatment during the first week post-
injury reduced that sustained effect in brain as well.
EVT901 treatment inhibits the recruitment of CCR2+
pro-inflammatory monocytes into the injured brain at
7 days after TBI and is neuroprotective
CCR2, the chemokine receptor for CCL2, is highly
expressed by pro-inflammatory monocytes and promotes
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Fig. 3 EVT901 treatment reduced the number of Ly6Cint-high inflammatory monocytes in the circulation. Blood was obtained from C57Bl/6 WT
mice at 1 and 6 weeks after TBI with or without EVT901. Leukocytes were isolated, stained with CD11b Ab and Ly6C Ab, and run on flow
cytometry. TBI significantly increased the absolute number of CD11b + Ly6Cint-high monocytes in the circulations, while EVT901 treatment reduced
the number. Two-way ANOVA revealed a significant effect of condition (F3,25 = 15.85, p < 0.000006, η2 = 0.67, power = 1.0), time (F1,32 = 5.71, p = 0.025,
η2 = 0.19, power = 0.63), time × treatment (F3,32 = 9.46, p < 0.0002, η2 = 0.54, power = 0.99). Tukey’s post hoc tests showed there was a
significant difference between TBI-vehicle and all other conditions, indicating that TBI increases monocyte numbers at 1 week but not
6 weeks and that EVT901 reduced this effect (*p < 0.05, ***p < 0.001). (n = 3 for sham and n = 4–7 for TBI)
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their recruitment into sites of tissue injury [67, 73].
CCR2 plays a critical role in recruiting Ly6Chigh mono-
cytes from the bone marrow to the peripheral blood
stream, and CCL2 leads monocytes directly to sites of
injury and inflammation [72]. Further, a recent study
demonstrated that CCR2 signaling is responsible for
80–90 % of the infiltrating monocytes in the injured
brain [19]. To evaluate the effects of p75NTR blockade
on the recruitment of this specific population of pro-
inflammatory monocytes, we used genetically modified
CCR2-RFP knock-in mice (CCR2+/RFP). The CCR2+/RFP
transgenic is a heterozygous mouse with bi-allelic ex-
pression of RFP and CCR2 [20, 50]. Because resident
microglia do not express CCR2 [20, 50], we were able
to use this reporter to identify monocytes of peripheral
origin. We were also able to detect RFP-positive cells in
the circulation at 7 days after TBI using flow cytometry
(Fig. 5a). We found that RFP-positive cells were
increased in the circulation at 7 days after TBI and that
EVT901 treatment reduced that population (Fig. 5a).
RFP-positive cells were also detected in the injured
brain at 7 days after TBI (Fig. 5c), as previously re-
ported [20]. To quantify the infiltrating RFP-positive
cells in the injured brain, we applied a proportional
area (P.A.) measurement based on previous studies [21,
52]. Brain tissue sections were obtained from the region
of interest (ROI) around the lesion (Fig. 5b). The RFP-
positive signal was highly increased in the injured brain
at 7 days after TBI, while EVT901 treatment significantly
reduced it (Fig. 5b–d), suggesting that EVT901 treatment
inhibits the infiltration of CCR2+ pro-inflammatory
monocytes. And consistent with our results in rat [43], we
found that treatment with EVT901 for 7 days after TBI in-
creased the amount of spared brain tissue (Fig. 5e). These
data suggest that blocking p75NTR with EVT901 reduces
the peripheral mobilization and expansion of CCR2+
TBI-Vehicle TBI-EVT901A B
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Fig. 4 EVT901 treatment reduced the recruitment of Ly6Cint-high monocytes into the injured brain at 1 and 6 weeks after TBI. The injured hemisphere
was dissected and homogenized. Single cells were obtained using percoll gradients and then stained with Abs against CD45, CD11b+, and Ly6C. a–c
TBI significantly increased the absolute number of Ly6Cint-high inflammatory monocytes in the injured brain, while EVT901 treatment
reduced the number. Two-way ANOVA revealed significant main effects of treatment (F3,36 = 6.19, p = 0.002, η2 = 0.4, power = 0.94) and
time (F1,3 = 5.10, p< 0.032, η2 = 0.15, power = 0.59). Tukey’s post hoc tests showed that TBI significantly increased CD45highCD11b + Ly6Cint-high inflammatory
monocytes in the injured brain at both 1 and 6 weeks after TBI, while EVT901 treatment reduced the number in the injured brain, *p< 0.05. (n= 3–4 for
sham and n= 5–7 for TBI)












































































































































Fig. 5 EVT901 treatment reduced CCR2+ monocytes in the injured brain and circulation and reduced tissue damage at 7 days after TBI. a Blood
was obtained from CCR2+/RFP Tg mice at 7 days after TBI with or without EVT901. One-way ANOVA showed that there was a significant difference
between vehicle and EVT901 after injury (F1,8 = 8.12, p = 0.03, η
2 = 0.58, power = 0.66) (n = 3/group). b Brain sections from CCR2+/RFP Tg mice were
obtained from the lesion area as shown (region of interest (ROI), from 1.5 mm anterior to 1.5 mm posterior of bregma). c CCR2+/RFP cells were
observed predominantly in the injured area. d RFP-positive signal was quantified and the proportional area (P.A. = the area of CCR2-RFP+ signal/
total area × 100) is shown. CCR2-RFP-positive signal was highly increased after TBI, and EVT901 treatment significantly reduced it. ANOVA showed
a significant effect of side (F1,28 = 35.03, p < 0.001, η2 = 0.83, power = 0.999), condition (F2,7 = 10.97, p = 0.007, η2 = 0.758, power = 0.922), side × condition
(F2,28 = 7.81, p < 0.02, η
2 = 0.69, p = 0.81), and section (F4,28 = 2.83, p < 0.043, η
2 = 0.288, power = 0.695). e EVT901 increased the spared tissue area after
TBI. One-way ANOVA showed a significant main effect of condition (F2,7 = 12.00, p = 0.005, η2 = 0.774, power = 0.942). Tukey’s post hoc test
comparing TBI-vehicle vs TBI-EVT901 was significant (*p = 0.0374), and comparing UN vs TBI-vehicle was also significant (†p = 0.005). Scale bars
in C = 1000 μm (left) and 100 μm (right). (n = 4/group)
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monocytes after injury, perhaps by reducing the chemo-
kine signaling from the brain by reducing the amount of
injury [43]. However, in light of the effects of EVT901 on
the induction of pro-inflammatory monocytes in vitro,
EVT901 may also act to reduce CCR2+ monocyte expan-
sion more directly by affecting myeloid cell proliferation
and differentiation through blocking p75NTR signaling.
Because CCR2+/RFP mice are heterozygotes, there
may be gene-dose-dependent effects that alter recruit-
ment of macrophages into the tissue [74]. Therefore,
we asked if EVT901 has comparable effects in C57BL/6
WT mice using alternative labeling strategies. To iden-
tify peripheral monocytes, we used CD45, which is
highly expressed on peripheral leukocytes. As an alter-
native to CCR2+/RFP, we used co-localization of CD45
and CCR2 immunostaining. We found that the co-
localization of positive signal for CD45 and CCR2 is in-
creased in the injured brain ROI at 7 days after TBI
and that EVT901 treatment significantly reduced this
signal (Fig. 6a, b). Consistent with CCR2+/RFP Tg mice,
tissue sparing (measured as the spared tissue area from
the lesion ROI sections) was enhanced in C57Bl/6 WT
treated with EVT901 compared to vehicle-treated mice
(Fig. 6c). Thus, we were able to confirm the effects of
EVT901 on CCR2+ cell recruitment using both Tg and
wild-type mice.
EVT901 treatment reduces F4/80+ monocytes/
macrophages in the injured brain after TBI
A recent study shows that CCR2 is required for recruit-
ing monocytes from the peripheral circulation into the
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Fig. 6 EVT901 treatment reduced CD45 + CCR2+ double-positive monocytes in the injured brain in C57Bl/6 WT mice at 7 days after TBI. a Brain
tissue sections were immuno-stained with CCR2 Ab and CD45 Ab. b TBI increased the CD45 + CCR2+ double-positive signal in the injured area,
while EVT901 treatment abrogated this effect. ANOVA revealed a significant main effect of condition (F2,6 = 14.50, p = 0.005, η
2 = 0.83, power = 0.96)
and section (F4,24 = 5.86, p = 0.002, η2 = 0.49, power = 0.96). Tukey’s post hoc test showed a significant difference between uninjured and
TBI-vehicle (p = 0.004). c Tissue area was significantly reduced by TBI, and this effect was abrogated by EVT901. One-way ANOVA showed a
main effect of condition (F2,6 = 14.06, p = 0.003, η2 = 0.82, power = 0.96). Tukey’s post hoc tests showed that TBI-vehilce, but not EVT901,
was different from uninjured control (p < 0.004). Scale bar in A = 1000 μm (left) and 100 μm (right). (n = 3 for UN and n = 5 for TBI groups)
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CCR2 is rapidly down-regulated when CCR2 monocytes
differentiate into tissue resident macrophages, it is only
possible to detect newly arrived CCR2 monocytes in
the tissues [20, 50]. To overcome this issue, F4/80, a
marker for mature monocytes/macrophages, was used
to estimate the total population of infiltrating periph-
eral monocytes in the injured brain at 7 days after TBI.
We found that the double-positive signal of CD45 and
F4/80 was increased in the injured brain at 7 days after
TBI (Fig. 7a) and that EVT901 treatment significantly
reduced this signal (Fig. 7a, b).
To confirm the immunohistochemical analysis, we ap-
plied flow cytometric analysis of brain homogenates, which
allowed us to estimate the absolute total number of infil-
trating peripheral monocytes/macrophages in the injured
brain. We found that the absolute total number of
CD45highF4/80+ cells was increased in the injured brain at
1 and 6 weeks after TBI, and yet again, EVT901 treatment
Fig. 7 EVT901 treatment attenuated the infiltration of peripheral monocytes/macrophages into the injured brain in WT mice. a Brain tissue
sections from C57BL/6 mice at 7 days after TBI were immuno-stained with CD45 and F4/80 Abs. b TBI increased the proportional area of CD45 +
F4/80+ double-positive signal in the injured brain, while EVT901 treatment reduced it. ANOVA indicated that there was a significant treatment
effect (F1,6 = 14.89, p = 0.005, η2 = 0.83, power = 0.97). Tukey’s post hoc test revealed a significant difference between uninjured vs TBI-vehicle (##p
= 0.004) and TBI-vehicle vs TBI-EVT901 (**p = 0.006). c–f Cells isolated from C57Bl/6 WT mice brains at 1 and 6 weeks after sham or TBI, with or
without EVT901, were stained with Abs against CD45, CD11b+, and F4/80. c, d TBI increased the absolute number of CD45highF4/80+ monocytes,
and EVT901 significantly reduced the number. Two-way ANOVA followed by Tukey’s post hoc tests showed that there was a significant effect of
condition (F3,36 = 4.06, p = 0.016, η
2 = 0.31, power = 0.779), but no effects of time. TBI increased CD45highF4/80+ cells in the injured brain compared
to sham, while EVT901 treatment abrogated this effect (*p < 0.05). e, f TBI significantly increased the absolute number of CD45highCD11b+ monocytes
in the injured brain, and EVT901 significantly reduced it. Two-way ANOVA showed a significant effect of condition (F3,35 = 9.02, p = 0.0002,
η2 = 0.5, power = 0.99), but no effect of time. Tukey’s post hoc tests showed a significant effect of injury and EVT901 at both 1 and 6 weeks
(*p < 0.05, **p < 0.001 compared to TBI-vehicle). Scale bar in A = 1000 (left) and 100 μm (right). (n = 3–4 for sham and n = 5–7 for TBI)
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significantly reduced these populations (Fig. 7c, d). In
addition, we examined total monocyte/macrophage popula-
tions in the injured brain using CD11b Ab, a common
marker for both immature and mature monocytes and
macrophages. We found that there was a significant in-
crease in CD45highCD11b+ monocytes in the injured brain
(Fig. 7e, f), and this increase, present at both 1 and 6 weeks,
was abrogated by the 1-week treatment with EVT901. In
contrast, the total number of CD45lowCD11b+ cells, which
represent the resident microglia, was not affected by TBI or
EVT901 (data not shown).
Blocking p75NTR signaling by EVT901 treatment
improves motor function after TBI and modifies the
multivariate syndromic effects of TBI on both immune
system and behavior
Previous studies show that prevention of early trafficking
of peripheral immune cells into the injured CNS results
in better behavioral outcomes and reduction of tissue
damage [13, 19, 20, 22–24].
The CCI-TBI protocol we used in the mouse in the
present study resulted in relatively minor motor deficits that
largely recovered over the 6 weeks after injury. However, we
did see evidence for a drug effect on some measures. To
analyze the full set of behavioral and associated inflamma-
tory biomarkers, we performed principal components ana-
lysis (PCA) to extract the global syndromic outcome
patterns. Consistent with these prior studies, we found that
blocking early trafficking of peripheral monocytes into the
CNS by EVT901 treatment after TBI reduced neurological
deficits. Using a battery of behavioral tests with TBI mice,
we found that fine motor functions performed on a beam
were significantly improved by EVT901 administered for
1 week after injury (Fig. 8c, d). Further, we found that TBI
significantly reduced the total volume of neocortex at
6 weeks, and EVT901 significantly reversed this when com-
pared to the vehicle-treated brain (Fig. 8b).
The PCA revealed five orthogonal principal compo-
nents that partitioned the shared variance between cellu-
lar and behavioral outcome measures at 6 weeks (Fig. 9,
and Additional file 1: Figure S1). PC1, which accounted
for 27 % of the total variance, appeared to describe the
coordinate increase in inflammatory markers and the de-
terioration of behavioral function seen after TBI (Fig. 9a),
providing a useful composite metric for the syndrome of
CCI-TBI in our mice: comparisons of sham and TBI
subjects using PC1 as a univariate measure showed a
significant increase in value (Fig. 9b). One week of treat-
ment with EVT901 dramatically lowered the PC1 z-
score values in mice with TBI, supporting the idea that
EVT9011 coordinately affected neuroinflammation and
behavioral outcomes.
Discussion
Our previous study using the novel p75NTR antagonist
EVT901 was initially aimed at blocking the well-







































Fig. 8 EVT901 treatment improved motor function and reduced brain damage after TBI. a Persistent fine motor coordination was evaluated by
beam walking for 6 weeks after TBI. The total number of footfaults was increased by TBI, and EVT901 reduced this deficit. Two-way ANOVA
revealed a significant main effect of injury (F1,26 = 48.996, p = 0.0000002, η2 = 0.65, power = 1), and a significant time × treatment effect
(F3,78 = 4.90, p = 0.04, η2 = 0.16, power = 0.9). Tukey’s post hoc tests revealed a significant difference between TBI-vehicle and TBI-EVT901 (*p = 0.04) and
sham and TBI (###p < 0.0001). b Unbiased stereological volumetric analysis showed a significant atrophy of cortex on the ipsilateral, but not contralateral
side of TBI. EVT901 treatment inhibited tissue atrophy compared to vehicle. T test (*p = 0.04). (n = 5 per group)
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documented effects of p75NTR signaling on apoptotic
cell death in CNS neurons and glia, and we showed
quite dramatic effects on measures of tissue sparing and
a variety of neurological outcomes in multiple models of
TBI in the rat [43]. The results also showed very dra-
matic reductions in histological measures of neuroin-
flammation and microglial activation. We wondered
whether EVT901 might be affecting neuroinflammatory
signals as well as apoptosis. However, we saw no evi-
dence for microglial expression of p75NTR in that study,
and aside from a few reports of p75NTR on microglial
cells in vitro [75, 76], there is little evidence for micro-
glial expression of p75NTR in the adult brain. However,
there have been isolated reports of p75NTR expression
in leukocytes [45, 46], (reviewed in [44]). We thus raised
the question as to whether p75NTR could also be in-
volved in the peripheral inflammation seen after TBI,
with consequences for the recruitment of monocytes/
macrophages into the injured brain. We found in mouse
TBI, a strong pro-inflammatory peripheral acute re-
sponse to CNS injury, and the accumulation of periph-
eral leukocytes, including pro-inflammatory monocytes
and CCR2+ cells, in the brain injury site at 1 and 6 weeks
after injury.
Seven days of treatment with EVT901 reduced the ef-
fects of each element of the combined blood and brain in-
flammatory response to CCI-TBI: it reduced the increased
expression of p75NTR on peripheral monocytes, it re-
duced the increase in numbers of pro-inflammatory
monocytes in the blood at 1 week after injury, and it re-
duced the invasion of peripheral myeloid cells (defined by
multiple phenotypic markers) into the brain. And consist-
ent with our previous work [43], EVT901 was neuropro-
tective and reduced post-TBI neurological deficits.
These results are consistent with the hypothesis that
EVT901 has both central and peripheral effects on in-
flammation by blocking p75NTR signaling in both
neural and peripheral immune cells, dampening the ef-
fects of central neuroinflammation by reducing both the
CNS damage caused by p75NTR apoptotic signaling and
the exacerbation of initial microglial activation by the
production and invasion of highly pro-inflammatory per-
ipheral monocytes. While the reduction in peripheral
inflammatory responses might be in part an indirect ef-
fect of the reduction of central injury, and therefore of
signaling (e.g., by DAMPs, CCL2, cytokines, or other
mediators), the strong inhibition by EVT901 of pro-
inflammatory responses to LPS in isolated monocytes in
vitro provides evidence for a direct effect.
The choice of injury model
We chose to use a controlled-cortical impact (CCI)
model of TBI in the mouse for these studies. These in-
juries are characterized by frank contusions of the cor-
tical mantle and disruption of the local blood-brain
barrier, although widespread diffuse injury also has been
documented [51, 77]. A significant proportion of human
TBI includes focal contusion injuries that may “bloom”
and expand over the first few days after injury [78, 79].
These injuries, with their frank breach of the blood-
brain barrier, are likely to be especially affected by inva-
sion of peripheral myeloid cells. Further, the presence of
an MRI-defined contusion injury in mild TBI is a strong
predictor of negative outcome [80]. Thus, treatments
that reduce the evolution of contusion injuries are likely
to be translatable to at least an important and potentially
















































Fig. 9 Multivariate principal component analysis (PCA). To understand the relationship of behavioral outcome and innate immune cell responses
at 42 days after TBI, PCA was used. This analysis yielded five dimensional PC-loading patterns accounting for 80.55 % of total variance (details in
Additional file 1: Figure S1). a Significant loading on PC1 indicated that more errors on the beam-walking tasks were associated with the numbers
of peripheral inflammatory immune cells in the brain and (less so) with increased pro-inflammatory monocytes in the blood. Bilateral paw placement,
a measure of recovery of cortical function, was inversely correlated between individual variables and PC1. Red arrow indicates a positive
relationship, while blue arrow indicates negative relationship. PCs 2–5 also showed associations between behavioral recoveries and inflammatory
markers (see Additional file 1: Figure S1). b Post hoc analysis of the main effects on PC1 (27.1 % of total variance) indicated that there is a significant
effect of injury (F1,39 = 21.412, p = 0.000, η2 = 0.380, power = 0.994) and of EVT901 treatment (F1,39 = 4.435, p = 0.042, η2 = 0.112, power = 0.535)
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Leukocyte invasion in TBI
Accumulating evidence shows that infiltration of periph-
eral monocytes/macrophages as well as neutrophils is an
important part of the inflammatory response to TBI.
Massive infiltration of peripheral immune cells into the
injured brain after TBI is a prevalent outcome resulting
in significant promotion of cell death and tissue damage,
inhibition of the wound healing process, and impairment
of neurological recovery. And several studies show that
blocking trafficking of peripheral monocytes into the
injured CNS results in better behavioral outcomes and
reduced tissue damage [13, 19, 20, 22, 24, 49, 81, 82].
The data from our prior work [13] and the current set
of studies in the mouse supports this view and also sug-
gests that the proliferation and differentiation of pro-
inflammatory monocytes in the circulation in response to
TBI contributes to the availability of pro-inflammatory
cells for recruitment to the brain. Somewhat in contrast to
these data, a recent study reports that a closed head injury
TBI did not significantly increase the population of
blood monocytes and saw a reduction in F4/80 macro-
phages at 30 days post-TBI. They also noted increases in
the anti-inflammatory M2 monocytes populations in the
circulation, suggesting that TBI produces an immune-
suppressive environment by reducing blood monocytes as
well as thymocytes [83]. That study used several monocyte
markers (B220−CD4−CD8−Nk1.1−Ly6G−CD11b+CD115+)
to identify the monocyte population, while we used
CD11b + Ly6Chigh for inflammatory monocytes, which are
increased at 1 week, but not 6 weeks, after TBI in the
circulation (Fig. 3). In addition, we also found that TBI
increases the population CD11b + F4/80+ mature
monocytes in the circulation at 1 week (unpublished
data). The apparent discrepancy may be due to the dif-
ferent markers used to identify different subsets of
peripheral monocytes, as peripheral monocytes gener-
ally display heterogeneous cell markers on their
surface depending on their stage of maturity (i.e., im-
mature vs mature), activation state (activated vs non-
activated), and polarization (pro-inflammatory M1
monocytes vs anti-inflammatory M2 monocytes). In
the current study, we only investigated the pro-
inflammatory monocyte populations as identified by
CD11b + Ly6Cint-high after TBI. It is also likely that the
initial pro-inflammatory response we noted leads to a
more chronic, immune-suppressive phenotype as also
noted in chronic SCI [25]. However, it is also clear that
there is a wide range of phenotypes that evolve from
the peripheral monocyte invasion of injured CNS (e.g.,
[49], and some of these are clearly neuroprotective
and promote repair [82].
While it is known that TBI and other CNS injuries
also produce an acute and persistent peripheral inflam-
matory response, the role of the peripheral immune
system in exacerbating or ameliorating the CNS injury
is not well understood [14], although much evidence
suggests that peripheral inflammation can influence
CNS function even in the absence of injury [84, 85].
The results of the current studies are consistent with
the idea that CNS injury produces signals that stimulate
the expansion of bone marrow myeloid cells via CCL2
signaling via CCR2 [72, 73], DAMPs [14], or other
mediators.
p75NTR and inflammation
The mechanisms of p75NTR signaling in inflamma-
tion are not known, and the possibility of p75NTR as
an inflammatory mediator has barely been explored
[44–46]. In the present study, blocking p75NTR with
EVT901 reduced the production of TNF-α in response
to LPS. EVT901 also reduced the LPS and pro-NGF in-
crease in p75NTR expression. We previously showed that
EVT901 also reduces the increase in p75NTR expression
induced by pro-NGF stimulation in cultured oligodendro-
cytes and oligodendrocyte precursor cells [43], which ac-
companied (and perhaps mediated) the reduced apoptotic
cell death produced by pro-NGF in these cells. The
mechanism for the autocrine-like response is unknown.
Further, we do not know if the p75NTR signaling path-
way in myeloid cells leads to apoptosis in peripheral
monocytes as it does in neurons an oligodendrocytes
[32, 86]. However, Choi and Freidman [87, 88] have
shown that the inflammatory cytokines IL-1β and TNF-
α increase p75NTR expression in neurons and astro-
cytes. This study emphasized that IL-1β induces
p75NTR through the p38MAPK pathway, while TNF-α
activates the NF-κB pathway in neurons and astrocytes,
promoting neuronal cell death and glia proliferation,
respectively. The production of high levels of IL-1β and
TNF-α in both the CNS and periphery after TBI thus
may be involved in the rather pronounced increases in
p75NTR expression in monocytes that we see after
TBI. LPS is recognized by monocytes and macrophages
through toll-like receptor (TLRs), which are involved in
the innate immune response to LPS by producing in-
flammatory cytokines, such as TNF-α [89]. LPS has
been shown to induce p75NTR expression on
monocyte-derived dendritic cells through the NF-κB
signaling pathway, suggesting that p75NTR expression
is enhanced by DAMPs or other pro-inflammatory
stimuli [90]. Both TNF-α and IL-1β receptors are
present on monocytes [91, 92], and IL-1β and TNF are
associated with NF-κB signaling in monocytes as well
[89, 93, 94]. We have not yet tested these various sig-
naling pathways with respect to the effects of EVT901
on peripheral monocytes.
While the evidence for a peripheral role of p75NTR in
peripheral inflammation is growing, the principal
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evidence in the present study comes from the modula-
tion of immune functions by EVT901. Since p75NTR is
a member of the TNF receptor superfamily (TNFRSF
16) [95], the potential for off-target effects, TNFR1 or 2
for example, should be considered. However, extensive
analysis of EVT901 binding and effects on a variety of
cognate and mutated TNFRSF constructs in vitro
showed a high degree of specificity of EVT901 for
p75NTR [43]. Nevertheless, further studies using con-
verging mechanisms to block p75NTR signaling are cer-
tainly warranted. Further, the ligand(s) involved in
peripheral immune actions of p75NTR are not known.
In the CNS, pro-NGF, pro-BDNF, beta-amyloid, and PrP
have been shown to bind and activate p75NTR signaling,
and this depends on the co-receptors involved including
tropomyosin receptor kinases (Trks) and sortilin [30,
32]. These same mediators may be present in the periph-
ery, and there is the possibility that the release from sites
of CNS injury could play a role in the primary activation
of peripheral monocytes, but this remains to be deter-
mined. Other possibilities for the role of p75NTR might
involve proteolytic processing and subsequent intracellu-
lar signaling (e.g., see [96]. This is an intriguing possibil-
ity in light of the apparent interaction between TNF and
p75NTR, since TACE and MMPs are involved in proteo-
lytic cleavage-related modulation of signaling in both
systems [33, 97, 98]. Another possibility is that p75NTR
can be involved in cell migration and proliferation by
interacting with α9β1 integrin [99], suggesting that it
may be contributing to recruitment of peripheral im-
mune cells into the CNS tissues. However, the role of
α9β1 integrin has yet to be described after CNS injury.
In addition, there is no evidence of p75NTR expres-
sion on microglia in the adult normal or injured CNS.
We have found that EVT901 did not affect the number
of CD45lowCD11b+ or F4/80+ microglia in the injured
brain by flow cytometric analysis. Further, our attempt
to detect p75NTR expression in microglia in the in-
jured brain failed. Thus, we have reached the conclu-
sion that the effect of EVT901 is not directly on
microglia in the injured brain but rather on the periph-
eral immune cells. Previously, we have seen that
EVT901 treatment reduced microglial activation in the
injured rat brain after TBI and conclude that this effect
is probably due to EVT901 reducing neuronal and
oligodendrocyte cell death, as well as reducing traffick-
ing of pro-inflammatory peripheral monocytes into the
injured brain.
Conclusions
We show that attenuation of peripheral Ly6Cint-high
pro-inflammatory monocytes by EVT901 treatment is
associated with a reduction in trafficking of Ly6Cint-high
inflammatory monocytes into the injured brain and
subsequent improvement of motor function (Figs. 3, 4,
5, 6, 7, and 8). There is strong evidence that EVT901
targets p75NTR dimerization and signaling in in vitro
studies and in vivo in the CNS [43]. While further stud-
ies will be needed to confirm that p75NTR is the pri-
mary target of EVT901 in immune cells, the data in
this study in combination with the rather limited litera-
ture on the role of p75NTR in immune cells raises the
possibility that p75NTR is an important mediator of
peripheral inflammation as well as a diverse, co-receptor-
dependent modulator of neuronal survival and growth in
the CNS. Beyond a recent report of co-localization of
p75NTR and trkA in human monocytes/macrophages
[44], little is known about the presence of p75NTR co-
effectors in immune cells, and the role(s) of p75NTR in
peripheral immunity may be as diverse as in the CNS.
However, the strong modulatory effects of EVT901 on
both central and peripheral inflammation suggest that
p75NTR represents a novel target for immune modula-
tion that favors neuroprotection and recovery after
CNS injury.
Additional file
Additional file 1: Figure S1. Complete PCA solution. To understand
the relationship of behavioral outcome and innate immune cell
responses, multivariate PC analysis was used. (A) PCA applies eigenvalue
decomposition to the entire matrix cross correlations of all outcomes and
clusters variables that move together as an integrated, optimally weighted
linear composite (PC) to maximally explain the variance in cross-correlation.
Once the first eigenvalue decomposition (PC1) is extracted, a second
orthogonal (uncorrelated) decomposition calculated accounting for the
second highest cluster of variance (PC2) and so on until all of the variance
in the data set is partitioned into sequentially numbered PCs. The PC
measures are rank ordered by the proportion of the total variance in
the dataset that they explain. Standardized statistical PC retention rules
are then applied to retain ‘significant’ PCs with eigenvalues > 1 and (B)
PCs above the ‘elbow of the scree plot. (C) Interpretation of PC content
based on PC loadings, which are equivalent to a pearson correlation
between each variable and the PC composites. The PC loading pattern
shows the contribution every single variable (outcome measures) on
the extracted PCs. This analysis yielded 5 dimensional PC loading
patterns (total, 80.55 % of variance). The PC1 module represented the
relationship between neurological outcome and pro-inflammatory
monocyte responses (27.13 % of variance). The individual PC score
(see Fig. 9b) for each subject is the sum of the multiplied loading by
the individual raw value of single outcome measures. The individual
PC scores are used to define the impact of experimental manipulations on
the relationship between outcome measures. (PDF 91 kb)
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